Answers are grounded in this paper and cite their sources.
Background Diabetic kidney disease (DKD) is one of the most common and devastating complications of diabetes and is strongly associated with acute kidney injury (AKI). However, nationwide evidence describing long-term mortality trends and the potential biological relationship between DKD and AKI remains limited. Methods We analyzed CDC WONDER mortality data (1999–2023) for deaths among adults aged ≥45 years in which both DKD and AKI were recorded as multiple causes on the death certificate. Joinpoint regression estimated age-adjusted mortality rates (AAMRs) and average annual percent changes (AAPCs); an autoregressive integrated moving average (ARIMA) model projected trend through 2046. Two-sample Mendelian randomization (MR) was used to explore potential genetic causal relationships, and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis examined shared mechanisms. Finally, a Chinese laboratory cohort derived from KingMed Diagnostics was used to describe the laboratory characteristics of individuals with diabetes, persistent pre-existing kidney dysfunction, and subsequent laboratory-defined AKI. Results A total of 330, 775 deaths among patients with coexisting DKD and AKI were recorded. The overall AAMR increased from 5.08 to 17.10 per 100, 000 between 1999 and 2023 (a 236.6% relative increase; AAPC, 4.96% [95% CI, 4.63%–5.30%]). All subgroups showed rising mortality, with the fastest growth among adults aged 45–54 years and the highest absolute AAMR in those aged ≥85 years. Geographic disparities were prominent, with the highest mortality burden in the South and Midwest. ARIMA projections indicated that annual deaths may reach approximately 47, 000 by 2046, with males consistently showing higher AAMRs. In MR analyses, the inverse-variance weighted estimate was an odds ratio (OR) of 1.123 (95% CI , 0.992–1.272; P = 0.068), whereas the weighted-median estimate was 1.145 (95% CI , 1.067–1.229; P < 0.001). Sensitivity analyses identified significant heterogeneity but no statistically significant evidence of directional horizontal pleiotropy. Enrichment analyses identified shared pathways including PI3K - Akt , MAPK , and cytokine-cytokine receptor signaling. In the descriptive Chinese laboratory cohort, 118 individuals with laboratory evidence of diabetes, persistent pre-existing kidney dysfunction, and subsequent laboratory-defined AKI were identified, of whom 58 (49.2%) met the serum creatinine-based criteria corresponding to KDIGO stage 3 AKI. Annual case counts varied over the observation period, peaking in 2024. Although this selected cohort cannot establish population-level incidence or risk. Conclusions The mortality burden among patients with coexisting DKD and AKI has substantially increased over the past 25 years and is projected to continue rising. These multiple-cause-of-death data do not establish deaths attributable to the combination. The KingMed laboratory cohort provided complementary descriptive evidence of laboratory-defined AKI among individuals with diabetes and persistent pre-existing kidney dysfunction.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: